The T-cell inhibitory molecule PD-L1 is expressed on a fraction of breast cancer cells. The
distribution of PD-L1 on the different subpopulations of breast cancer cells is not well …

Upon analysis of 636 primary breast carcinoma patient samples, we have found that
programmed cell death ligand 1 (PD-L1) mRNA expression is associated with tumor …

The expression of PD‐L1 in breast cancer is associated with estrogen receptor negativity,
chemoresistance and epithelial‐to‐mesenchymal transition (EMT), all of which are common …

Purpose PD-L1 is thought to play an important role in the antitumor immune response. In this
study, we investigated the expression of PD-L1 within breast tumor subsets to better define …

To better understand the expression pattern of programmed death-ligand 1 (PD-L1)
expression in different breast cancer types, we characterized PD-L1 expression in tumor and …

Here we report the expression of programmed cell death ligand 1/2 (PD‐L1/L2) in breast
and colon cancer stem cells (CSC s). The stemness of these cells was confirmed by their …

Triple-negative breast cancer (TNBC) is a type of breast malignancy characterized by a high
proliferative rate and metastatic potential leading to treatment failure, relapse, and poor …

The associations between programmed cell death ligand 1 (PD-L1) and the prognosis of
various cancers have always been a research topic of considerable interest. However, the …

Summary PD-L1 and PD-L2 constitute an important antitumor immune response. In breast
cancer, their prognostic value is still to be defined. In this study, we investigate the …

Objectives: Breast cancer is the most commonly diagnosed cancer, and it is a leading cause
of cancer-related deaths in females worldwide. Triple-negative breast cancer (TNBC) …